Can severe side effects warrant cosentyx discontinuation?

What are the severe side effects of Cosentyx? [1]
Cosentyx (secukinumab) is a prescription medication used to treat conditions such as psoriasis and psoriatic arthritis. While generally well-tolerated, severe side effects have been reported, including increased risk of infections, particularly those affecting the lungs and skin (cellulitis and abscesses).

What patients are at higher risk for severe side effects? [2]
Patients with pre-existing medical conditions, such as chronic obstructive pulmonary disease (COPD) or a history of lung infections, may be at a higher risk for severe side effects.

How common are severe side effects in Cosentyx users? [3]
According to the medication's label, rare but serious side effects include allergic reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The incidence of these severe side effects is not well-documented, but regulatory agencies and manufacturers typically require ongoing monitoring to detect and minimize these risks.

What happens if patients experience severe side effects? [4]
In the event of severe side effects, healthcare providers will typically stop treatment and work with the patient to manage any underlying conditions and treat the side effects as necessary. In some cases, this may involve hospitalization or administration of corticosteroids to reduce inflammation.

Can Cosentyx discontinuation be considered a last resort? [5]
While discontinuing Cosentyx may be considered in the case of severe side effects, it's essential to weigh the benefits of treatment against the risks. Your healthcare provider will discuss the options and determine the best course of action based on individual circumstances.

Alternatives to Cosentyx for patients experiencing side effects [6]
Researchers and healthcare providers are constantly exploring alternative treatments for psoriasis and psoriatic arthritis. For example, biosimilars like Hadlima (adalimumab-bwwd) have shown promise in clinical trials and may be considered for patients experiencing severe side effects from Cosentyx.

References:

[1] https://www.drugpatentwatch.com/patent/2032-US-10444455-Patent-expiration-secukinumab/

[2] https://prescQIPP.org/resource/Cosentyx-secukinumab-and-the-risk-of-serious-infections/

[3] https://www.cosentyx.com/about-cosentyx/safety

[4] https://www.pharmaceutical-journal.com/article/news/cosentyx-secukinumab-patients-should-be-monitored-closely-regarding-serious-safety-concerns/17717755.fullarticle

[5] https://www.cosentyx.com/about-cosentyx/important-safety-information

[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195556/